Slide 1: Preclinical characterization of IMG-007, a high-affinity, non-depleting anti-OX40 monoclonal antibody
Preclinical characterization of IMG-007, a high-affinity, non-depleting anti-OX40 monoclonal antibody for the treatment of inflammatory and autoimmune disease Jon Tuncel, PhD Jonatan Tuncel1, Chongtian Guo2, Kurinji Pandiyan1, Ben Porter-Brown1, and Kristin Yarema1 1ImageneBio, San Diego, CA, United
Slide 2: Disclosures
Disclosures Disclosures Jonatan Tuncel, Kurinji Pandiyan, Ben Porter-Brown, and Kristin Yarema are employees of ImageneBio and may hold equity interests. Chongtian Guo is an employee of Miragene, may hold equity interests, and is a former employee of the private company Inmagene, which conducted sev
Slide 3: Atopic dermatitis is a heterogeneous disease with high unmet need, underpinned by diverse immune endotypes
Atopic dermatitis is a heterogeneous disease with high unmet need, underpinned by diverse immune endotypes AD is a chronic heterogeneous inflammatory disease with several immune endotypes ~40-50% of patients show incomplete or no response to Type 2 biologics (e.g., dupilumab)1 (1) 48-56% of pati
Slide 4: OX40 inhibition has the potential to modulate multiple inflammatory pathways of relevance in AD
OX40 inhibition has the potential to modulate multiple inflammatory pathways of relevance in AD OX40 is a key co-stimulatory pathway regulating T cell activation and effector function in AD1 Upstream OX40 blockade broadly modulates T cell activation and effector differentiation across inflammato
Slide 5: IMG-007: A non-depleting OX40 antagonist designed to suppress pathogenic immunity while preserving immune balance
IMG-007: A non-depleting OX40 antagonist designed to suppress pathogenic immunity while preserving immune balance High affinity supports potent inhibition of OX40–OX40L engagement Limits effector T cell activation and polarization Reduces clonal expansion of pathogenic memory T cells May enhan
Slide 6: Minimal Fcγ receptor binding prevents depletion of OX40+ cells through ADCC
Minimal Fcγ receptor binding prevents depletion of OX40+ cells through ADCC IMG-007 show minimal FcγR binding across FcγRI/II/III, with only residual CD64 interaction and fully preserved FcRn binding No NK cell–mediated cytotoxicity (ADCC) across concentrations tested Minimal release of NK-der
Slide 7: Minimal Fcγ receptor binding limits agonistic signaling by preventing OX40 crosslinking
Minimal Fcγ receptor binding limits agonistic signaling by preventing OX40 crosslinking IMG-007 show minimal FcγR binding across FcγRI/II/III, with only residual CD64 interaction and fully preserved FcRn binding No meaningful agonistic signaling detected across a broad set of test conditions Th
Slide 8: IMG-007 shows rocatinlimab-level OX40L inhibition without Fc-mediated effector function
IMG-007 shows rocatinlimab-level OX40L inhibition without Fc-mediated effector function IMG-007 is comparable to rocatinlimab in OX40L binding and downstream NFκB inhibition IMG-007 shows potent, dose-dependent suppression of IFNγ production in primary T cell assays Inhibition of OX40-OX40L Inhi
Slide 9: IMG-007 suppresses T cell expansion and T cell-driven pathology in a xenogeneic GvHD model
IMG-007 suppresses T cell expansion and T cell-driven pathology in a xenogeneic GvHD model Xenogeneic GvHD models provide a functional readout of T cell activation and expansion Relevant model systems for human OX40 biology, as murine OX40L engages OX40 on human donor T cells Weekly IMG-007 do
Slide 10: Summary of preclinical attributes of IMG-007
Summary of preclinical attributes of IMG-007 o IMG-007 is a novel OX40-targeting antibody combining potent pathway inhibition with an Fc-silenced backbone o Aglycosylation (N297A) with limited Fcγ receptor binding confers silenced ADCC function and dominant antagonistic activity o Preclinical studie
Slide 11: IMG-007 in AD: rapid clinical improvement with a favorable safety profile in Phase 1b/2a
IMG-007 in AD: rapid clinical improvement with a favorable safety profile in Phase 1b/2a Four-week IMG-007 treatment with only three doses resulted in 87% mean reduction in EASI score from baseline at week 20 Most patients achieved ≥75%, and nearly one-third achieved ≥90%, improvement in EASI by
Slide 12: IMG-007: the first non-depleting, antagonistic OX40 receptor–targeting antibody in advanced clinical development
IMG-007: the first non-depleting, antagonistic OX40 receptor–targeting antibody in advanced clinical development IMG-007 continues to be further characterized both biologically and clinically in an ongoing Phase 2 development program C O N F I D E N T I A L 12
Slide 13: Acknowledgment
Acknowledgment The authors thank the patients, investigators, and study site personnel for their invaluable contributions to this research. Please visit Poster 1036, “Preclinical characterization of IMG-007, a high-affinity, non-depleting anti-OX40 monoclonal antibody for the treatment of inflammato